With 2.32 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.06 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.88 whereas the lowest price it dropped to was $7.6. The 52-week range on KZIA shows that it touched its highest point at $39.05 and its lowest point at $2.86 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 2.18.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KZIA was up-trending over the past week, with a rise of 0.74%, but this was down by -4.12% over a month. Three-month performance dropped to -14.57% while six-month performance rose 66.34%. The stock lost -7.91% in the past year, while it has lost -56.89% so far this year. A look at the trailing 12-month EPS for KZIA yields -29.44 with Next year EPS estimates of 0.00. For the next quarter, that number is -0.01. This implies an EPS growth rate of 50.00% for this year and 100.00% for next year.
Float and Shares Shorts:
On 2025-08-29, short shares totaled 12148.0, which was 109.00000000000001 higher than short shares on 1753920000. In addition to Dr. John Edwin Friend II, M.D. as the firm’s Chief Executive Officer & MD, Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC serves as its Company Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. EBITDA for the full year was -$22.79M.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KZIA since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KZIA analysts setting a high price target of 15.305755 and a low target of 13.264722, the average target price over the next 12 months is 14.285238. Based on these targets, KZIA could surge 87.8% to reach the target high and rise by 62.76% to reach the target low. Reaching the average price target will result in a growth of 75.28% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$44.913 being high and -$44.913 being low. For KZIA, this leads to a yearly average estimate of -$44.913.
